Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Biotinidase deficiency: A treatable cause of opticospinal syndrome in young adults.

Van Iseghem V, Sprengers M, De Zaeytijd J, Sindic CJM, Willekens B, Dermaut B, Hemelsoet D, Laureys G.

Mult Scler Relat Disord. 2019 Jul;32:64-65. doi: 10.1016/j.msard.2019.04.025. Epub 2019 Apr 24.

PMID:
31035122
2.

Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required.

Bauters T, Bordon V, Laureys G, Dhooge C.

Bone Marrow Transplant. 2019 Feb 25. doi: 10.1038/s41409-019-0488-2. [Epub ahead of print] No abstract available.

PMID:
30804487
3.

Cladribine in myasthenia gravis: A case urging for prudence.

Laureys G, De Bleecker JL.

Muscle Nerve. 2019 May;59(5):E38. doi: 10.1002/mus.26446. Epub 2019 Feb 22. No abstract available.

PMID:
30758837
4.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2019 Apr;38(15):2690-2705. doi: 10.1038/s41388-018-0595-3. Epub 2018 Dec 11.

PMID:
30538293
5.

[Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis].

Zephir H, Puyade M, Gueguen A, Michel L, Terriou L, Dive D, Laureys G, Mathey G, Labauge P, Marjanovic Z, Pugnet G, Badoglio M, Lansiaux P, Yakoub-Agha I, Béguin Y, Farge D.

Bull Cancer. 2019 Jan;106(1S):S92-S101. doi: 10.1016/j.bulcan.2018.11.002. Epub 2018 Dec 5. French.

6.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

7.

Genes at the Crossroad of Primary Immunodeficiencies and Cancer.

Derpoorter C, Bordon V, Laureys G, Haerynck F, Lammens T.

Front Immunol. 2018 Nov 1;9:2544. doi: 10.3389/fimmu.2018.02544. eCollection 2018. Review.

8.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.

Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12.

PMID:
30442501
9.

EBV-NMDA double positive encephalitis in an immunocompromised patient.

Garré J, Sprengers M, Van Melkebeke D, Laureys G.

J Neurol Sci. 2019 Jan 15;396:76-77. doi: 10.1016/j.jns.2018.11.001. Epub 2018 Nov 3. No abstract available.

PMID:
30419370
10.

Pinpointing a potential role for CLEC12B in cancer predisposition through familial exome sequencing.

Derpoorter C, Vandepoele K, Diez-Fraile A, Vandemeulebroecke K, De Wilde B, Speleman F, Van Roy N, Lammens T, Laureys G.

Pediatr Blood Cancer. 2019 Feb;66(2):e27513. doi: 10.1002/pbc.27513. Epub 2018 Oct 23.

PMID:
30350915
11.

Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, 1H and 31P MRS, and clinical and cognitive testing.

Cambron M, Reynders T, Debruyne J, Reyngoudt H, Ribbens A, Achten E, Laureys G.

J Neurol. 2018 Nov;265(11):2614-2624. doi: 10.1007/s00415-018-9039-9. Epub 2018 Sep 5.

PMID:
30187159
12.

Short-term perspectives of parents and teachers on school reintegration of childhood brain tumour survivors.

Vanclooster S, Bilsen J, Peremans L, Van der Werff Ten Bosch J, Laureys G, Willems E, Genin S, Van Bogaert P, Paquier P, Jansen A.

Dev Neurorehabil. 2019 Jul;22(5):321-328. doi: 10.1080/17518423.2018.1498553. Epub 2018 Jul 17.

PMID:
30015543
13.

Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.

Morgenstern DA, Pötschger U, Moreno L, Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A, Canete A, Elliot M, Wieczorek A, Laureys G, Kogner P, Malis J, Ruud E, Beck-Popovic M, Schleiermacher G, Valteau-Couanet D, Ladenstein R.

Pediatr Blood Cancer. 2018 Nov;65(11):e27363. doi: 10.1002/pbc.27363. Epub 2018 Jul 17.

PMID:
30015396
14.

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.

Corrias MV, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, Träger C, Yáñez Y, Dallorso S, Varesio L, Luksch R, Laureys G, Valteau-Couanet D, Canete A, Pöetschger U, Ladenstein R, Burchill SA.

Pediatr Blood Cancer. 2018 Jul;65(7):e27052. doi: 10.1002/pbc.27052. Epub 2018 Mar 30.

15.

Drug shortages in a pediatric stem cell transplantation ward: Challenges and implications. A 5-year bilan.

Claus B, Bauters T, Laureys G.

J Oncol Pharm Pract. 2019 Jun;25(4):841-846. doi: 10.1177/1078155218765627. Epub 2018 Mar 29.

PMID:
29592767
16.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

Laureys G, Willekens B, Vanopdenbosch L, Deryck O, Selleslag D, D'Haeseleer M, De Becker A, Dubois B, Dierickx D, Perrotta G, De Wilde V, van Pesch V, Straetmans N, Dive D, Beguin Y, Van Wijmeersch B, Theunissen K, Kerre T, Van de Velde A.

Acta Neurol Belg. 2018 Jun;118(2):161-168. doi: 10.1007/s13760-018-0905-0. Epub 2018 Mar 13.

17.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

18.

Severe anaphylactic reaction following anti-thymocyte globulin administration in a pediatric stem cell transplantation patient.

Bauters T, Bordon V, Willems J, De Wilde B, Laureys G.

J Oncol Pharm Pract. 2018 Apr;24(3):232-234. doi: 10.1177/1078155217699989. Epub 2017 Mar 16.

PMID:
29284348
19.

Attending school after treatment for a brain tumor: Experiences of children and key figures.

Vanclooster S, Bilsen J, Peremans L, Van der Werff Ten Bosch J, Laureys G, Willems E, Genin S, Van Bogaert P, Paquier P, Jansen A.

J Health Psychol. 2017 Oct 1:1359105317733534. doi: 10.1177/1359105317733534. [Epub ahead of print]

PMID:
28988492
20.

Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.

Van Roy N, Van Der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K.

Clin Cancer Res. 2017 Oct 15;23(20):6305-6314. doi: 10.1158/1078-0432.CCR-17-0675. Epub 2017 Jul 14.

21.

Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia.

Bauters T, Buts S, Bordon V, Laureys G.

J Oncol Pharm Pract. 2018 Oct;24(7):537-539. doi: 10.1177/1078155217717325. Epub 2017 Jul 6.

PMID:
28682150
22.

Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.

Amoroso L, Erminio G, Makin G, Pearson ADJ, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, Luksch R, Ladenstein R, Haupt R, Garaventa A; SIOPEN Group.

Cancer Res Treat. 2018 Jan;50(1):148-155. doi: 10.4143/crt.2016.511. Epub 2017 Mar 21.

23.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN).

Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2.

PMID:
28259608
24.

Chemotherapy drug shortages in paediatric oncology: A 14-year single-centre experience in Belgium.

Bauters T, Claus BO, Norga K, Huys I, Simoens S, Laureys G.

J Oncol Pharm Pract. 2016 Dec;22(6):766-770. Epub 2015 Oct 6.

PMID:
26447099
25.

Safety in the use of vaseline during oxygen therapy: the pharmacist's perspective.

Bauters T, Van Schandevyl G, Laureys G.

Int J Clin Pharm. 2016 Oct;38(5):1032-4. doi: 10.1007/s11096-016-0365-7. Epub 2016 Aug 1.

PMID:
27480983
26.

Multidrug-resistant cytomegalovirus infection in a pediatric stem cell transplantation patient.

Bauters T, Bordon V, Florin L, Padalko E, Andrei G, Gillemot S, Fiten P, Opdenakker G, Snoeck R, Laureys G.

Antiviral Res. 2016 Aug;132:149-53. doi: 10.1016/j.antiviral.2016.05.020. Epub 2016 Jun 11. No abstract available.

PMID:
27296901
27.

Diplopia as presenting sign of Turcot syndrome.

Ninclaus VG, Walraedt S, Baert E, Laureys G, Leroy BP, De Zaeytijd J.

Int Ophthalmol. 2017 Feb;37(1):275-278. doi: 10.1007/s10792-016-0246-z. Epub 2016 May 3.

PMID:
27143045
28.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

29.

Evaluation of timing of first vaccination in children after hematopoietic allogeneic stem cell transplantation.

Bauters T, Bordon Cueto De Braem V, Schelstraete P, Van Lancker S, Laureys G, Benoit Y, Dhooge C.

Eur J Oncol Nurs. 2016 Apr;21:212-4. doi: 10.1016/j.ejon.2015.10.006. Epub 2015 Nov 29.

PMID:
26645948
30.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

31.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

32.

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Øra I, Schulte JH, Caron HN, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):222-30. doi: 10.1007/s00259-014-2909-1. Epub 2014 Sep 30.

33.

β₂-adrenergic receptors protect axons during energetic stress but do not influence basal glio-axonal lactate shuttling in mouse white matter.

Laureys G, Valentino M, Demol F, Zammit C, Muscat R, Cambron M, Kooijman R, De Keyser J.

Neuroscience. 2014 Sep 26;277:367-74. doi: 10.1016/j.neuroscience.2014.07.022. Epub 2014 Jul 24.

PMID:
25064060
34.

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.

Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Pearson AD, Ladenstein R, Burchill SA.

J Clin Oncol. 2014 Apr 1;32(10):1074-83. doi: 10.1200/JCO.2013.53.3604. Epub 2014 Mar 3.

PMID:
24590653
35.

β₂-adrenergic agonists modulate TNF-α induced astrocytic inflammatory gene expression and brain inflammatory cell populations.

Laureys G, Gerlo S, Spooren A, Demol F, De Keyser J, Aerts JL.

J Neuroinflammation. 2014 Jan 30;11:21. doi: 10.1186/1742-2094-11-21.

36.

Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.

Cambron M, Mostert J, Haentjens P, D'Hooghe M, Nagels G, Willekens B, Heersema D, Debruyne J, Van Hecke W, Algoed L, De Klippel N, Fosselle E, Laureys G, Merckx H, Van Wijmeersch B, Vanopdenbosch L, Verhagen W, Hupperts R, Hengstman G, Michiels V, Van Merhaegen-Wieleman A, De Keyser J.

Trials. 2014 Jan 25;15:37. doi: 10.1186/1745-6215-15-37.

37.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
38.

Emesis control by aprepitant in children and adolescents with chemotherapy.

Bauters TG, Verlooy J, Robays H, Benoit Y, Laureys G.

Int J Clin Pharm. 2013 Dec;35(6):1021-4. doi: 10.1007/s11096-013-9842-4. Epub 2013 Sep 4.

PMID:
24002338
39.

Living related liver transplantation in an adult patient with hepatocellular adenoma and carcinoma 13 years after bone marrow transplantation for Fanconi anemia: A case report.

Colle I, Laureys G, Raevens S, Libbrecht L, Leroy JG, Reyntjens K, Geerts A, Rogiers X, Troisi RI, Hoehn H, Schindler D, Hanenberg H, De Wilde V, Van Vlierberghe H.

Hepatol Res. 2013 Sep;43(9):991-8. doi: 10.1111/hepr.12043. Epub 2013 May 15.

40.

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.

Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F.

PLoS One. 2013;8(1):e52321. doi: 10.1371/journal.pone.0052321. Epub 2013 Jan 4.

41.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

42.

Benign myelitis as a first presentation of systemic sarcoidosis: importance of early diagnosis and treatment.

Antoine S, Van Den Bossche B, Vandenhove J, De Braekeleer K, Laureys G.

Acta Neurol Belg. 2013 Mar;113(1):81-3. doi: 10.1007/s13760-012-0122-1. Epub 2012 Sep 14. No abstract available.

PMID:
22975831
43.

N-cadherin in neuroblastoma disease: expression and clinical significance.

Lammens T, Swerts K, Derycke L, De Craemer A, De Brouwer S, De Preter K, Van Roy N, Vandesompele J, Speleman F, Philippé J, Benoit Y, Beiske K, Bracke M, Laureys G.

PLoS One. 2012;7(2):e31206. doi: 10.1371/journal.pone.0031206. Epub 2012 Feb 15.

44.

Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.

Bordon V, Padalko E, Benoit Y, Dhooge C, Laureys G.

Pediatr Transplant. 2012 Mar;16(2):144-50. doi: 10.1111/j.1399-3046.2011.01634.x. Epub 2012 Jan 31.

PMID:
22288846
45.

White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Cambron M, D'Haeseleer M, Laureys G, Clinckers R, Debruyne J, De Keyser J.

J Cereb Blood Flow Metab. 2012 Mar;32(3):413-24. doi: 10.1038/jcbfm.2011.193. Epub 2012 Jan 4. Review.

46.

miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.

De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J.

Clin Cancer Res. 2011 Dec 15;17(24):7684-92. doi: 10.1158/1078-0432.CCR-11-0610. Epub 2011 Oct 26.

47.

Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder?

Garabedian L, Struyf S, Opdenakker G, Sozzani S, Van Damme J, Laureys G.

Eur Cytokine Netw. 2011 Sep;22(3):148-53. doi: 10.1684/ecn.2011.0290. Review.

48.

The expression and role of CXC chemokines in colorectal cancer.

Verbeke H, Struyf S, Laureys G, Van Damme J.

Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):345-58. doi: 10.1016/j.cytogfr.2011.09.002. Epub 2011 Oct 14. Review.

PMID:
22000992
49.

Late onset painful cold-aggravated myotonia: three families with SCN4A L1436P mutation.

Bissay V, Keymolen K, Lissens W, Laureys G, Schmedding E, De Keyser J.

Neuromuscul Disord. 2011 Aug;21(8):590-3. doi: 10.1016/j.nmd.2011.05.006. Epub 2011 Jun 12.

PMID:
21664816
50.

Practical implications for the administration of 13-cis retinoic acid in pediatric oncology.

Bauters TG, Laureys G, Van de Velde V, Benoit Y, Robays H.

Int J Clin Pharm. 2011 Aug;33(4):597-8. doi: 10.1007/s11096-011-9519-9. Review.

PMID:
21544558

Supplemental Content

Loading ...
Support Center